Bausch + Lomb (BLCO) Stock Forecast, Price Target & Predictions
BLCO Stock Forecast
Bausch + Lomb stock forecast is as follows: an average price target of $19.50 (represents a -2.50% downside from BLCO’s last price of $20.00) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
BLCO Price Target
The average price target for Bausch + Lomb (BLCO) is $19.50 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $21.00 to $18.00. This represents a potential -2.50% downside from BLCO's last price of $20.00.
BLCO Analyst Ratings
According to 5 Wall Street analysts, Bausch + Lomb's rating consensus is 'Buy'. The analyst rating breakdown for BLCO stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Bausch + Lomb Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 22, 2024 | Doug Miehm | RBC Capital | $20.00 | $16.98 | 17.79% | - |
| May 06, 2024 | Patrick Wood | Morgan Stanley | $18.00 | $13.60 | 32.35% | -10.00% |
| May 08, 2023 | Yi Chen | H.C. Wainwright | $19.00 | $18.16 | 4.65% | -5.00% |
| Jul 28, 2022 | Vijay Kumar | Evercore ISI | $21.00 | $14.86 | 41.32% | 5.00% |
The latest Bausch + Lomb stock forecast, released on Jul 22, 2024 by Doug Miehm from RBC Capital, set a price target of $20.00, which represents a 17.79% increase from the stock price at the time of the forecast ($16.98), and a 0.00% decrease from BLCO last price ($20.00).
Bausch + Lomb Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $20.00 | $19.00 |
| Last Closing Price | $20.00 | $20.00 | $20.00 |
| Upside/Downside | -100.00% | - | -5.00% |
In the current month, the average price target of Bausch + Lomb stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Bausch + Lomb's last price of $20.00. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 22, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Jul 10, 2024 | Raymond James | - | Outperform | Initialise |
| May 06, 2024 | Morgan Stanley | - | Overweight | Upgrade |
| Feb 26, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| May 08, 2023 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 26, 2022 | RBC Capital | - | Outperform | Initialise |
Bausch + Lomb's last stock rating was published by RBC Capital on Jul 22, 2024. The company gave BLCO a "Outperform" rating, the same as its previous rate.
Bausch + Lomb Financial Forecast
Bausch + Lomb Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $1.01B | $1.03B | $931.00M | $996.00M | $942.00M | - | $889.00M |
| Avg Forecast | $1.35B | $1.25B | $1.28B | $1.17B | $1.26B | $1.17B | $1.17B | $1.06B | $1.11B | $990.68M | $963.69M | $895.80M | $966.92M | $949.72M | $908.52M | $889.00M |
| High Forecast | $1.36B | $1.26B | $1.29B | $1.18B | $1.27B | $1.19B | $1.18B | $1.07B | $1.11B | $1.02B | $968.44M | $900.22M | $971.70M | $954.41M | $908.52M | $903.64M |
| Low Forecast | $1.34B | $1.24B | $1.27B | $1.16B | $1.25B | $1.12B | $1.16B | $1.05B | $1.10B | $974.14M | $956.15M | $888.80M | $959.36M | $942.30M | $908.52M | $869.84M |
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 5 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.02% | 1.07% | 1.04% | 1.03% | 0.99% | - | 1.00% |
Bausch + Lomb's average Quarter revenue forecast for Dec 23 based on 6 analysts is $1.11B, with a low forecast of $1.10B, and a high forecast of $1.11B. BLCO's average Quarter revenue forecast represents a 9.85% increase compared to the company's last Quarter revenue of $1.01B (Sep 23).
Bausch + Lomb EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 5 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | $40.00M | $43.00M | $58.00M | $110.00M | $147.00M | - | $151.00M |
| Avg Forecast | $259.52M | $239.97M | $246.55M | $224.45M | $242.44M | $224.71M | $224.67M | $203.99M | $212.29M | $190.11M | $184.93M | $171.91M | $185.55M | $182.25M | $174.35M | $170.60M |
| High Forecast | $260.80M | $241.15M | $247.77M | $225.56M | $243.63M | $228.55M | $225.78M | $205.00M | $213.34M | $195.16M | $185.85M | $172.75M | $186.47M | $183.15M | $174.35M | $173.41M |
| Low Forecast | $257.49M | $238.09M | $244.63M | $222.70M | $240.54M | $215.11M | $222.92M | $202.40M | $210.63M | $186.94M | $183.49M | $170.56M | $184.10M | $180.83M | $174.35M | $166.92M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.21% | 0.23% | 0.34% | 0.59% | 0.81% | - | 0.89% |
6 analysts predict BLCO's average Quarter EBITDA for Dec 23 to be $212.29M, with a high of $213.34M and a low of $210.63M. This is 430.72% upper than Bausch + Lomb's previous annual EBITDA (Sep 23) of $40.00M.
Bausch + Lomb Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 5 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | $-84.00M | $-32.00M | $-88.00M | - | $-15.00M | - | $20.00M |
| Avg Forecast | $99.70M | $79.73M | $79.40M | $56.55M | $88.26M | $54.72M | $45.20M | $24.75M | $59.53M | $66.17M | $51.24M | $47.63M | $78.44M | $84.02M | $68.94M | $82.09M |
| High Forecast | $100.34M | $80.24M | $79.91M | $56.91M | $88.83M | $64.97M | $45.49M | $24.91M | $73.54M | $81.43M | $51.57M | $47.94M | $78.94M | $84.56M | $68.94M | $83.84M |
| Low Forecast | $98.69M | $78.92M | $78.59M | $55.97M | $87.37M | $44.46M | $44.74M | $24.50M | $42.02M | $40.72M | $50.72M | $47.14M | $77.64M | $83.16M | $68.94M | $79.79M |
| Surprise % | - | - | - | - | - | - | - | - | - | -1.27% | -0.62% | -1.85% | - | -0.18% | - | 0.24% |
Bausch + Lomb's average Quarter net income forecast for Jul 22 is $68.94M, with a range of $68.94M to $68.94M. BLCO's average Quarter net income forecast represents a 244.69% increase compared to the company's last Quarter net income of $20.00M (Mar 22).
Bausch + Lomb SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 5 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | $418.00M | $417.00M | $418.00M | $386.00M | $381.00M | - | $343.00M |
| Avg Forecast | $517.39M | $478.41M | $491.54M | $447.48M | $483.34M | $448.00M | $447.92M | $406.68M | $423.23M | $379.02M | $368.69M | $342.72M | $369.93M | $363.35M | $347.58M | $340.12M |
| High Forecast | $519.95M | $480.77M | $493.97M | $449.69M | $485.72M | $455.66M | $450.13M | $408.69M | $425.32M | $389.09M | $370.51M | $344.41M | $371.76M | $365.14M | $347.58M | $345.72M |
| Low Forecast | $513.35M | $474.67M | $487.70M | $443.99M | $479.56M | $428.85M | $444.42M | $403.51M | $419.92M | $372.69M | $365.81M | $340.04M | $367.04M | $360.51M | $347.58M | $332.79M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.10% | 1.13% | 1.22% | 1.04% | 1.05% | - | 1.01% |
Bausch + Lomb's average Quarter SG&A projection for Dec 23 is $423.23M, based on 6 Wall Street analysts, with a range of $419.92M to $425.32M. The forecast indicates a 1.25% rise compared to BLCO last annual SG&A of $418.00M (Sep 23).
Bausch + Lomb EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 5 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.24 | $-0.09 | $-0.25 | - | $-0.04 | - | $0.06 |
| Avg Forecast | $0.28 | $0.23 | $0.23 | $0.16 | $0.25 | $0.16 | $0.13 | $0.07 | $0.17 | $0.19 | $0.15 | $0.14 | $0.22 | $0.24 | $0.20 | $0.23 |
| High Forecast | $0.29 | $0.23 | $0.23 | $0.16 | $0.25 | $0.18 | $0.13 | $0.07 | $0.21 | $0.23 | $0.15 | $0.14 | $0.22 | $0.24 | $0.20 | $0.24 |
| Low Forecast | $0.28 | $0.22 | $0.22 | $0.16 | $0.25 | $0.13 | $0.13 | $0.07 | $0.12 | $0.12 | $0.14 | $0.13 | $0.22 | $0.24 | $0.20 | $0.23 |
| Surprise % | - | - | - | - | - | - | - | - | - | -1.28% | -0.63% | -1.85% | - | -0.18% | - | 0.24% |
According to 5 Wall Street analysts, Bausch + Lomb's projected average Quarter EPS for Jul 22 is $0.20, with a low estimate of $0.20 and a high estimate of $0.20. This represents a 243.87% increase compared to BLCO previous annual EPS of $0.06 (Mar 22).
Bausch + Lomb Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| AKYA | Akoya Biosciences | $2.84 | $7.90 | 178.17% | Buy |
| COO | Cooper Companies | $110.53 | $298.00 | 169.61% | Buy |
| ANGO | AngioDynamics | $7.60 | $17.00 | 123.68% | Buy |
| ATRC | AtriCure | $27.99 | $49.57 | 77.10% | Buy |
| HAE | Haemonetics | $75.61 | $104.33 | 37.98% | Buy |
| TFX | Teleflex | $241.53 | $304.09 | 25.90% | Buy |
| BDX | Becton, Dickinson and Company | $231.59 | $280.55 | 21.14% | Buy |
| WST | West Pharmaceutical Services | $309.18 | $345.33 | 11.69% | Buy |
| BLCO | Bausch + Lomb | $20.00 | $19.50 | -2.50% | Buy |
| ALC | Alcon | $96.65 | $93.34 | -3.42% | Buy |
| HOLX | Hologic | $81.72 | $78.92 | -3.43% | Buy |
| RMD | ResMed | $238.03 | $205.14 | -13.82% | Hold |
| ICUI | ICU Medical | $176.22 | $135.00 | -23.39% | Buy |
| ATR | AptarGroup | $153.07 | $100.00 | -34.67% | Buy |
BLCO Forecast FAQ
Is Bausch + Lomb a good buy?
Yes, according to 5 Wall Street analysts, Bausch + Lomb (BLCO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 80.00% of BLCO's total ratings.
What is BLCO's price target?
Bausch + Lomb (BLCO) average price target is $19.5 with a range of $18 to $21, implying a -2.50% from its last price of $20. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Bausch + Lomb stock go up soon?
According to Wall Street analysts' prediction for BLCO stock, the company can go down by -2.50% (from the last price of $20 to the average price target of $19.5), up by 5.00% based on the highest stock price target, and down by -10.00% based on the lowest stock price target.
Can Bausch + Lomb stock reach $30?
BLCO's average twelve months analyst stock price target of $19.5 does not support the claim that Bausch + Lomb can reach $30 in the near future.
What are Bausch + Lomb's analysts' financial forecasts?
Bausch + Lomb's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $4.67B (high $4.71B, low $4.59B), average EBITDA is $895.81M (high $902.97M, low $880.97M), average net income is $212.93M (high $224.2M, low $201.06M), average SG&A $1.79B (high $1.8B, low $1.76B), and average EPS is $0.605 (high $0.637, low $0.572). BLCO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $5.06B (high $5.08B, low $5.02B), average EBITDA is $970.5M (high $975.29M, low $962.91M), average net income is $315.38M (high $317.4M, low $312.18M), average SG&A $1.93B (high $1.94B, low $1.92B), and average EPS is $0.896 (high $0.902, low $0.887).
Did the BLCO's actual financial results beat the analysts' financial forecasts?
Based on Bausch + Lomb's last annual report (Dec 2022), the company's revenue was $3.77B, beating the average analysts forecast of $3.71B by 1.45%. Apple's EBITDA was $457M, missing the average prediction of $712.75M by -35.88%. The company's net income was $15M, missing the average estimation of $313.48M by -95.22%. Apple's SG&A was $1.48B, beating the average forecast of $1.42B by 4.01%. Lastly, the company's EPS was $0.0429, missing the average prediction of $0.892 by -95.19%. In terms of the last quarterly report (Sep 2023), Bausch + Lomb's revenue was $1.01B, beating the average analysts' forecast of $990.68M by 1.65%. The company's EBITDA was $40M, missing the average prediction of $190.11M by -78.96%. Bausch + Lomb's net income was $-84M, missing the average estimation of $66.17M by -226.95%. The company's SG&A was $418M, beating the average forecast of $379.02M by 10.28%. Lastly, the company's EPS was $-0.24, missing the average prediction of $0.188 by -227.61%